Abstract
Foscarnet (sodium phosphonoformate) is an antiviral with a high degree of efficacy against members of the herpes simplex virus family. We studied the toxicity of single doses of intravitreally administered foscarnet in the albino rabbit. Eyes were evaluated clinically and by light microscopy. Data demonstrated that doses ranging from 20 to 1000 micrograms per 0.1 milliliter are nontoxic to the retina, suggesting that foscarnet may be useful in the treatment of acute retinal necrosis and cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Acheson JF, Shah SM, Spalton DJ et al. Treatment of CMV retinitis in an AIDS patient. Br J Ophthalmol 1987; 71: 810–16.
Boezi JA. The antiherpes virus action of phosphonoacetate. Pharmac Ther 1979; 4: 231–43.
Chou E, Walmsey S, Fanning M et al. Treatment of CMV retinitis with trisodium phosphonoformate (foscarnet). Suppl Invest Ophthalmol Vis Sci 1987; 28: 394.
Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl) guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986; 314: 801–05.
Culbertson WW, Blumenkranz MS, Pepose JS et al. Varicella zoster virus is a cause of the acute retinal necrosis syndrome. Ophthalmology 1986; 93: 559–69.
Farthing C, Anderson MG, Ellis ME et al. Treatment of cytomegalovirus pneuminitis with foscarnet (trisodium phosphonoformate) in patients with AIDS. J Med Vir 1987; 22: 157–62.
Felsentein D, D'Amico DJ, Hirsch MS et al. Treatment of cytomegalovirus retinitis with 9-[2-dydroxy-1 (hydroxymethyl) ethoxymethyl] guanine. Ann Intern Med 1985; 103: 377–80.
Henderly DE, Freeman WR, Cousey DM et al. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 1987; 94: 425–32.
Holland GN, Sakamoto MJ, Hardy D et al. Treatment of cytomegalovirus retinopathy in patients with acquired immunodeficiency syndrome. Arch Ophthalmol 1986; 104: 1794–1800.
Maurice DM. Injection of drugs into the vitreous body. In: Leopold IH, Burns RP, eds. Symposium on ocular therapy, Vol. 9. New York: John Wiley, 1976: 59–72.
McKinlay MA, Otto MJ. Recent developments in antiviral chemotherapy. Infect Dis Clin North Am 1987; 1: 479–86.
Peyman GA, Vastine DW, Raichand M. Postoperative endophthalmitis: Experimental aspects and their clinical application. Trans Am Acad Ophthalmol Otolaryngol 1978; 85: 374–85.
Polak A, Odds FC, Ludin E et al. Correlation of susceptibility test results in vitro with response in vivo: Ketacona-zole therapy in a systemic candidiasis model. Chemotherapy 1985; 31: 395–404.
Ringden O, Wilczek H, Lonnquist B et al. Foscarnet for cytomegalovirus infections. Lancet 1985; 1: 1503–04.
Singer DRJ, Fallon TJ, Schulenburg WE et al. Foscarnet for cytomegalovirus retinitis. Ann Intern Med 1985; 103: 962.
Smith KO, Galloway KS, Ogilvie KK, Cheriyan VO. Synergism among B1OLF-62, phosphonoformate, and other antiherpetic compounds. Antimicrob Agents Chemother 1982; 22: 1026–30.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
She, SC., Peyman, G.A. & Schulman, J.A. Toxicity of intravitreal injection of foscarnet in the rabbit eye. Int Ophthalmol 12, 151–154 (1988). https://doi.org/10.1007/BF00137142
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00137142